688131 皓元医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)5.3087.9757.4845.2789.350
总资产报酬率 ROA (%)2.6354.0654.1583.2726.474
投入资产回报率 ROIC (%)2.9924.6074.7083.7857.555

边际利润分析
销售毛利率 (%)50.76447.10447.96545.16851.444
营业利润率 (%)11.74310.31510.4326.82614.474
息税前利润/营业总收入 (%)15.93211.77712.0208.51314.577
净利润/营业总收入 (%)9.8368.0528.7196.71814.105

收益指标分析
经营活动净收益/利润总额(%)136.897157.529154.935161.741107.449
价值变动净收益/利润总额(%)0.308-5.763-5.709-3.7238.085
营业外收支净额/利润总额(%)-0.485-7.6070.645-0.1060.995

偿债能力分析
流动比率 (X)2.0782.1312.5191.8802.217
速动比率 (X)1.2901.3401.5970.8961.109
资产负债率 (%)50.01549.38747.24339.73935.183
带息债务/全部投入资本 (%)38.12736.62233.21224.23215.367
股东权益/带息债务 (%)146.703155.175177.147282.011492.789
股东权益/负债合计 (%)98.913100.885110.658150.611183.280
利息保障倍数 (X)3.7535.3757.9065.025-342.766

营运能力分析
应收账款周转天数 (天)78.95173.08777.06175.32063.743
存货周转天数 (天)331.779303.811351.690359.057344.748